ERBB2 and breast cancer: The majority of studies describe the association of molecular variations of key cancer genes with pCR, such as MYC amplification in a cohort of 51 patients distributed in luminal A (22), luminal B (14), HER2+ (8), and TN (7) BC subtypes, all of them treated with neoadjuvant anthracycline-cyclophosphamide followed by taxanes.